Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal Polyps
Tezepelumab therapy led to significantly greater reductions in the size of nasal polyps, the severity of nasal congestion and sinonasal symptoms, and the use of nasal-polyp surgery and systemic glucocorticoids than placebo in adults with severe, uncontrolled chronic rhinosinusitis with nasal polyps. (Funded by AstraZeneca and Amgen; WAYPOINT ClinicalTrials.gov number, NCT04851964.).
Authors
- Julie McLaren
- Claudia Chen
- Gun Almqvist
- Åsa Hellqvist
- Sandhia S Ponnarambil
- Shankar Jagadeesh
- Oliver Pfaar (ORCID: https://orcid.org/0000-0003-4374-9639)
- Vaishali S. Mankad
- Stella E. Lee (ORCID: https://orcid.org/0000-0001-6563-6606)
- Claire Hopkins (ORCID: https://orcid.org/0000-0003-3993-1569)
- Ayman Megally
- Ting Li (ORCID: https://orcid.org/0000-0002-3815-5601)
- Joaquim Mullol
- Lila Bahadori
- Mary Kay Margolis
- Brian J. Lipworth
- J. Mackay
- Martin Desrosiers
- Joseph K. Han
Institutions
- AstraZeneca (United Kingdom) (GB)
- Brigham and Women's Hospital (US)
- Amgen (United States) (US)
- St Thomas' Hospital (GB)
- Harvard University (US)
- Eastern Virginia Medical School (US)
- Philipps University of Marburg (DE)
- University of Dundee (GB)
- Ninewells Hospital (GB)
- Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (ES)
- St. Thomas Hospital (CA)
- Centre Hospitalier de l’Université de Montréal (CA)
- AstraZeneca (Sweden) (SE)
- AstraZeneca (Spain) (ES)
- AstraZeneca (United States) (US)
- Universitat de Barcelona (ES)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1056/nejmoa2414482
- Citations
- 107
- Primary Topic
- Sinusitis and nasal conditions
- Type
- article
- Field-Weighted Citation Impact
- 197.73
Funders
- Amgen
- AstraZeneca